Weekly Investment Analysts’ Ratings Updates for DBV Technologies (DBVT)

A number of firms have modified their ratings and price targets on shares of DBV Technologies (NASDAQ: DBVT) recently:

• 10/13/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/5/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/27/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/24/2024 – DBV Technologies had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.
• 9/19/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/11/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/3/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 8/26/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 8/18/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

DBV Technologies Trading Down 2.3 %

Shares of NASDAQ DBVT opened at $0.69 on Monday. The stock has a market capitalization of $66.93 million, a PE ratio of -0.83 and a beta of 0.67. DBV Technologies S.A. has a twelve month low of $0.50 and a twelve month high of $2.48. The stock has a fifty day simple moving average of $0.81 and a 200-day simple moving average of $1.00.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The business had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.42 million. During the same quarter last year, the company earned ($0.26) earnings per share. On average, equities analysts predict that DBV Technologies S.A. will post -1.43 earnings per share for the current year.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies comprises about 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.